SG Americas Securities LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 3.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 628,510 shares of the company’s stock after selling 22,974 shares during the period. SG Americas Securities LLC owned 0.06% of Teva Pharmaceutical Industries worth $11,326,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. Beach Investment Counsel Inc. PA bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $48,000. Byrne Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $52,000. Finally, Industrial Alliance Investment Management Inc. bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.
Insider Activity
In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Up 0.6 %
NYSE:TEVA traded up $0.11 during trading hours on Friday, reaching $17.49. The company had a trading volume of 4,669,458 shares, compared to its average volume of 6,931,503. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market cap of $19.81 billion, a price-to-earnings ratio of -42.63, a P/E/G ratio of 1.21 and a beta of 0.88. The business’s 50-day simple moving average is $17.83 and its two-hundred day simple moving average is $16.35. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $19.08.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- 3 Warren Buffett Stocks to Buy Now
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 9/30 – 10/4
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.